Publications

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. by VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG. published in Antimicrob. Agents Chemother. 2013; 57 (6): 2809-2814

Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. by Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS and Pfaller MA published in Clin. Infect. Dis. 2013; 56 (12): 1724-1732

An evaluation of vancomycin susceptibility testing for methicillin-resistant S. aureus: A comparison of Etest and three automated testing methods. by Rybak MJ, Vidaillac C, Sader H, Rhomberg P, Salimnia H, Briski L, Wanger A and Jones R published in J. Clin. Microbiol. 2013; 51 (7): 2077-2081

Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and non-fermentative Gram-negative bacilli. by Mendes RE, Alley MR, Sader HS, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (6): 2849-2857

Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin or vancomycin from USA hospitals (2008–2011). by Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (7): 3178-3181

Linezolid surveillance results for the United States: LEADER Surveillance Program 2011. by Flamm RK, Mendes RE, Ross JE, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (2): 1077-1081

Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). by Sader HS, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 417-422

Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute (API) results for 2007-2011. by Jones RN, Glick T, Sader HS, Flamm RK, Ross JE, Rhomberg PR and Edson DC published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 357-360

Contemporary potencies of minocycline and tetracycline HCL tested against gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria. by Jones RN, Wilson ML, Weinstein MP, Stilwell MG and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 402-405

Contemporary tetracycline susceptibility testing: Doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing gram-positive pathogens. by Jones RN, Stilwell MG, Wilson ML and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 69-72

More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA. by Jones RN, Sader HS, Flamm RK and Watters AA published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 110-112

Activities of carbapenem and comparator agents against contemporary U.S. Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. by Morrow BJ, Pillar CM, Deane J, Sahm D, Lynch AS, Flamm RK, Peterson J and Davies TA. published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 412-416

The genetic environment of the cfr gene and the presence of other mechanisms account for the very high linezolid resistance of the Staphylococcus epidermidisisolate 426-3147L. by LaMarre J, Mendes RE, Szal T, Schwarz S, Jones RN and Mankin AS published in Antimicrob. Agents Chemother. 2013; 57 (3): 1173-1179

Background and rationale for revised Clinical Laboratory Standards Institute (CLSI) interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. by Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ and Jones RN published in Clin. Infect. Dis. 2013; 56 (9): 1301-1309

Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: Report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). by Jones RN, Sader HS, Mendes RE and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 107-109

Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. by Vaara M, Sader HS, Rhomberg PR, Jones RN and Vaara T published in J. Antimicrob. Chemother. 2013; 68 (3): 636-639

Candida guilliermondii and other species of Candida misidentified as Candida famata: Assessment by Vitek2, ITS sequence analysis and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in two global surveillance programs. by Castanheira M, Woosley LN, Diekema DJ, Jones RN and Pfaller MA published in J. Clin. Microbiol. 2013; 51 (1): 117-124

Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010. by Castanheira M, Deshpande LM, Farrell SE, Shetye S, Shah N and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (2): 210-213

Activity of MK-3118, a new oral glucan synthase inhibitor tested against Candida spp. by two international methods (CLSI and EUCAST). by Pfaller MA, Messer SA, Motyl MR, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2013; 68 (4): 858-863

In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. by Pfaller MA, Messer SA, Motyl MR, Jones RN and Castanheira M published in Antimicrob. Agents Chemother. 2013; 57 (2): 1065-1068

Determination of disk diffusion and MIC quality control guidelines for GSK2251052: A novel boron antibacterial. by Ross JE, Scangarella-Oman NE and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 437-439

Update of dalbavancin spectrum and potency in the USA; Report from the SENTRY Antimicrobial Surveillance Program (2011). by Jones RN, Sader HS and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2013; 75 (3): 304-307

Surveillance of dalbavancin potency and spectrum in the United States (2012). by Jones RN, Flamm RK and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 122-123

Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: Selecting potent surrogate ß-lactam markers to predict ceftaroline activity against clinically-indicated species. by Jones RN, Flamm RK, Sader HS and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 89-93

Antimicrobial activity of ceftaroline-avibactam tested against recent clinical isolates from USA medical centers (2010-2011). by Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (4): 1982-1988

Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). by Sader HS, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 61-68

Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). by Farrell DJ, Flamm RK, Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 86-88

Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2013; 41 (4): 337-342

In vitro activity of a carbapenem and novel beta-lactamase (BL) inhibitor (I) combination (RPX2003/RPX7009) tested against contemporary populations of Gram-negative organisms, Lead author: Castanheira M, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Activity of the Fluoroketolide Solithromycin (SOL) Tested against Bacterial Species Associated with Significant Community-Acquired Bacterial Pneumonia (CABP) and other Gram-positive (GP) organisms, Lead author: Castanheira M, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Tigecycline Activity Tested against Resistant Surveillance Subsets of Clinical Bacteria Collected Worldwide (2011), Lead author: Flamm R, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Ceftaroline and Comparator Potency among Nine USA Census Regions: Report from the 2011 Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program, Lead author: Sader HS, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Antimicrobial Activity of Ceftaroline Tested against Staphylococci with Reduced Susceptibility to Linezolid, Daptomycin or Vancomycin from USA Hospitals (2008-2011), Lead author: Sader HS, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Antimicrobial Activity of Ceftaroline Combined with Avibactam Tested Against Bacteria Collected from Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in USA Medical Centers (2011), Lead author: Sader HS, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Activity of the Novel Antimicrobial Combination Ceftolozane/Tazobactam, Tested Against Bacterial Isolates in USA Hospitals from Patients with Pneumonia (2011), Lead author: Sader HS, presented at ID Week, October 17 – 21, 2012, San Diego, CA

A Multi-Site Study Comparing an 18-24h Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Dalbavancin Using Fastidious and non-Fastidious Gram- Positive Organisms, Lead author: Holliday, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of Ceftaroline-Avibactam Tested Against Contemporary Clinical Isolates from USA Medical Centers (2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Avibactam Reverts the Ceftazidime (CAZ) MIC₉₀ of a Recent Set of European Clinical Isolates of Gram-negative Bacteria Back to the Epidemiological Cut-off Value, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Spectrum and Potency of Ceftaroline-Avibactam Tested Against ESBL-Phenotype and Carbapenem-Resistant Enterobacteriaceae Collected from USA Hospitals (2009-2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of BAL30072, Alone and in Combination with Meropenem Tested Against Gram-Negative Bacteria Causing Serious Infections in Hospitals from China, India, Latin America and South East Asia-Pacific, Lead author: Rhomberg PR, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Activity of the Novel Antimicrobial Ceftolozane/Tazobactam Tested Against Contemporary Clinical Strains from USA Hospitals (2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of Six Seachaid Pharmaceuticals Investigational Compounds Tested against Gram-positive Strains, Lead author: Mendes RE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity and Spectrum of a Seachaid Pharmaceuticals Investigational Compound (SP2078) Tested against Gram-positive Pathogens, Lead author: Mendes RE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

In Vitro Activity of KPI-10 Tested Against a Global Collection of Acinetobacter spp. Including Multi-Drug Resistant (MDR) Strains, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

KPI-10 In Vitro Activity Tested Against Pathogens Commonly Associated with Community-Acquired Bacterial Pneumonia Infections, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

KPI-10, a Novel Fluoroquinolone Tested Against Neisseria gonorrhoeae including Ciprofloxacin Non-Susceptible and Penicillin Non-Susceptible Strains, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

In Vitro Activity of KPI-10 Tested Against Pathogens Commonly Associated with Urinary Tract infections, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Activity of RPX2003/RPX7009 (RPX3/9), a Carbapenem Combined with a Novel &#223-lactamase Inhibitor Tested Against Clinical Isolates Producing Defined Enzymes, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Pre-clinical Evaluation of a Carbapenem/ß-Lactamase Inhibitor Combination (RPX2003/RPX7009) Tested Against Serine-carbapenemase-producing Pathogens, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Activity of MK-3118, a New Oral Glucan Synthase Inhibitor, Tested Against Aspergillus spp. using Two Reference Broth Microdilution Methods, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA